Digitisation | December 16, 2025
Accenture invests in Ryght AI to revolutionize clinical trials
Ryght AI tackles these hurdles with its AI Site Twin platform
Ryght AI tackles these hurdles with its AI Site Twin platform
The study also showed a clear dose-dependent trend, with the 75 mg QD group outperforming the 50 mg QD cohort
The Phase 3 HER2CLIMB-05 trial showed a 35.9% reduction in risk for patients treated with TUKYSA
The new centre brings advanced corneal procedures pioneered in India
At the trial’s pre-specified interim analysis, giredestrant achieved a hazard ratio of 0.70, marking a statistically significant improvement in invasive disease-free survival
Dr Reddy’s will pay Immutep US$ 20 million upfront and could deliver as much as US$ 349.5 million in regulatory and commercial milestones
Columvi combined with gemcitabine and oxaliplatin dramatically extends survival in people with relapsed or refractory diffuse large B-cell lymphoma
76 of 180 long COVID-associated genes also linked to ME
It's an acquisition that aims at forming one of the US's largest oncology trial networks
MRI is particularly valuable in pediatric care due to its non-invasive nature
Subscribe To Our Newsletter & Stay Updated
